Recruiting NCT06216964
Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s).
- Who it may be relevant to
- Registry conditions: Chlamydia Trachomatis, Neisseria Gonorrhoeae, Uncomplicated Infections. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this study is to evaluate the negativation time of chlamydial and gonococcal PCRs after treatment for urogenital, oropharyngeal and anal infections.
Interventions
- Diagnostic test Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)
Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
Primary outcome measures
- Estimate the rate of negativation of NAATs performed at the various sites of CT infection [Time frame: 4 weeks after initiation of treatment]
Eligibility criteria
Inclusion criteria
- \- Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection.
- Over 18 years of age
- Male or female
- Who have had an uncomplicated CT and/or NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections).
- Subject affiliated to a social health insurance scheme
- Subject able to understand the aims and risks of the research and to give dated and signed informed consent
Exclusion criteria
- \- Complicated CT and/or NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome).
- Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant.
- Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.).
- Subject under court protection
- Subject under guardianship or curatorship
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- Service du Trait d'Union — Strasbourg
Identifiers
NCT: NCT06216964 · 9188